ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Teprotumumab for thyroid eye disease-associated superior ophthalmic vein periphlebitis: a case series.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the clinical and radiologic response of thyroid eye disease (TED)-associated superior ophthalmic vein periphlebitis (SOVP) to teprotumumab treatment.
methodsA retrospective chart review was performed at three institutions until June 2026. Patients with active moderate-to-severe TED with concomitant extraocular muscle (EOM) inflammation who underwent orbital magnetic resonance imaging (MRI) before teprotumumab initiation and after the 4th and 8th infusion were included. SOVP was defined as high signal intensity of the SOV wall on short tau inversion recovery (STIR) MRI. Demographic, clinical, and radiologic data were analyzed. Changes in Clinical Activity Score (CAS), Hertel exophthalmometric measurements, logMAR visual acuity, and SOV diameter were compared before and after treatment.
resultsAmong 131 patients treated with teprotumumab, 7 patients (5.3%; 4 men and 3 women) demonstrated unilateral SOVP. Inflammation of the superior rectus/levator palpebrae superioris complex was observed in 6 of 7 patients. Following treatment, CAS decreased significantly from 3.6 to 0.3 (P = 0.017), and Hertel measurements decreased from 20.1 mm to 17.7 mm (P = 0.027). LogMAR visual acuity showed no significant change (- 0.07 vs. -0.09; P = 0.317). STIR MRI demonstrated complete resolution of SOV wall hyperintensity in all patients, accompanied by complete resolution of EOM inflammation. The mean vertical SOV diameter decreased significantly from 3.99 mm to 2.21 mm (P = 0.018).
conclusionsAll patients with TED-associated SOVP demonstrated complete radiologic resolution, with significant reduction in SOV diameter and improvement in disease activity and proptosis, supporting SOVP as a reversible inflammatory manifestation of active TED.
Indexed as
Identifiers
42702683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.